10 hrs ago
Drew Barrymore: "I don't think I'm a good actor"
Drew Barrymore attends Hollywood Stands Up To Cancer Event with contributors American Cancer Society and Bristol Myers Squibb hosted by Jim Toth and Reese Witherspoon and the Entertainment Industry Foundation on Jan. 28, 2014, in Culver City, Calif.
Trending on the Topix Network
Mon Mar 10, 2014
BMS earmarks ten-year old Irish API plant for closure
Bristol-Myers Squibb says 160 jobs will be affected in Ireland as changing market demand drives the closure of an API plant.
Courthouse News Service
Plavix Marketing Claims Kicked to West Virginia
Accused of falsely marketing Plavix as superior to aspirin to sell it for about 100 times more, Bristol-Myers Squibb and Sanofi-Aventis must in state court, a federal judge ruled.
Fri Mar 07, 2014
The Motley Fool
Arrowhead Research Surges as It Advances Its Drug for Hepatitis B into Phase 2
The company won approval from Hong Kong regulators to start a phase 2a trial for its ARC-520 drug for hepatitis B. ARC-520 will be dosed alongside Bristol-Myers ' Hepatitis B drug Baraclude, a therapy that generates more than a billion in annual sales for Bristol.
Thu Mar 06, 2014
Vansen Pharma Appoints To Its Board Of Advisors
Mr. Moghaddam is an accomplished pharmaceutical executive with over 25 years of experience in both - Myers Squibb Canada, Linson Pharma Inc. , Allergan Canada, and E-Z-EM Inc. U.S. .
The Motley Fool
Bristol-Myers Squibb's Blockbuster Immunotherapy Opportunity
Losing the race Sadly for Bristol-Myers, nivolumab probably won't be the first PD-1 drug approved for the advanced melanoma indication.
160 jobs to go at Bristol-Myers Squibb
Bristol-Myers Squibb is to close its manufacturing facility in Cruiserath, Co Dublin, by the end of 2015 with the loss of 130 jobs.
Press release distribution, EDGAR filing, XBRL, regulatory filings
Our Ref. MH9547 ISIN Code. XS1039390... )--POHJOLA BANK PLC ISSUE OF GBP 50,000,000 FLOATING RATE NOTES DUE 27 FEB 2015 SERIES 163 TRANCHE 1 MTN ISSUE NAME.
Wed Mar 05, 2014
HIV and Hepatitis
CROI 2014: HIV Attachment Inhibitor BMS-663068 Shows Good Safety and Efficacy in Phase 2b
Combination therapy using a novel HIV attachment inhibitor demonstrated good safety and effectiveness, offering the promise of a new antiretroviral class that may be particularly beneficial for people with extensive resistance to current drugs, according to a report at the 21st Conference on Retroviruses and Opportunistic Infections this week in ... (more)
The Motley Fool
3 Stocks to Get on Your Watchlist
I follow quite a lot of companies, so the usefulness of a watchlist for me cannot be overstated.
The Washington Post
Bristol-Myers Experimental AIDS Medicine Controls Virus in Study
Bristol-Myers Squibb Co.' s experimental HIV drug controlled the virus as well as the company's older treatment Reyataz in a study that suggests the medicine may help difficult-to-treat patients.
Jim Cramer: Ghost-Town Sectors Are Hopping
Yesterday we had rallies in a couple of segments that were nothing short of stupendous.
Tue Mar 04, 2014
SVR12 Results from Phase IIa Study Evaluating Simeprevir and Daclatasvir in Hepatitis C Presented
March 4, 2014 - Medivir AB today announced that study results from a phase IIa trial evaluating simeprevir, a once-daily protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB, in combination with daclatasvir, an investigational once-daily NS5A inhibitor developed by Bristol-Myers Squibb , with and without ribavirin, in patients ... (more)
Bristol-Myers Squibb's Management Presents at Cowen Health Care Conference
Well, good morning and welcome to the Bristol-Myers Squibb session of Cowen's 34th Annual Healthcare Conference.
Daily Dividend Report: SXT, BMY, KRFT, AMAT, MR
Sensient Technologies has declared a regular quarterly cash dividend of $0.25 per share, an increase of 9% per share.
The Washington Post
AbbVie Seeks Approval for Hepatitis C Combo on Study Result
AbbVie Inc.'s combination hepatitis C therapy cured almost all patients in a late-stage study, moving the company closer to marketing a treatment that will compete with Gilead Sciences Inc. and Bristol-Myers Squibb Co.
Mon Mar 03, 2014
Durable melanoma remission seen with Bristol immunotherapy drug
A drug that uses the body's own immune system to kill cancer cells has produced lasting remissions - some as long as two years - in patients with melanoma that had spread to other parts of the body, according to data published on Monday.
Bristol-Myers Squibb Announces Dividend
The quarterly dividend will be payable on May 1, 2014, to stockholders of record at the close of business on April 4, 2014.
Digital Post Production
LUNGevity Foundation Receives Major Grant for Education Initiative
Progress in understanding lung cancer and treatment approaches has accelerated dramatically in the past several years after many slow decades.
Gilead CEO Becomes Billionaire on $84,000 Hepatitis Drug
John C. Martin, the chief executive officer of Gilead Sciences Inc. , has become a billionaire on the prospects of a powerful new hepatitis C drug that's attracting scrutiny from payers and activists over its $1,000 per pill price tag.